A cytochrome oxidase gene Grho7DLH, Grho7DLH protein, amplification primer set and applications

By identifying and applying the Grho7DLH gene of Gentiana scabra, we verified its function in catalyzing the formation of loganic acid from 7-deoxyserosolic acid, filling the gap in the biosynthetic pathway of iridoid glycosides, realizing the sustainable production of iridoid glycosides, and promoting the modernization of traditional Chinese medicine.

CN123063360APending Publication Date: 2026-11-10QINGDAO YANDING CELL BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611391804.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

In the existing technology, the key enzyme catalyzing the oxidation of 7-deoxystrychnine to loganic acid in the biosynthetic pathway of safflower gentian glycosides has not been discovered, resulting in unstable production of safflower gentian glycosides and limiting the development of the safflower gentian industry.

Method used

We provided the cytochrome oxidase gene Grho7DLH from Gentiana scabra and its encoded protein Grho7DLH. Through heterologous expression and in vitro enzymatic reactions, we verified its function in catalyzing the conversion of 7-deoxyserologinic acid to loganic acid. We also designed amplification primers for gene amplification and applied it to the synthesis of iridoid glycosides in synthetic biology.

Benefits of technology

This study revealed the catalytic mechanism of loganic acid formation in Gentiana scabra, providing a gene target for increasing the content of iridoid glycosides and enabling the sustainable production of iridoid glycoside active ingredients, thus reducing dependence on wild resources.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063360A_ABST
    Figure CN123063360A_ABST
Patent Text Reader

Abstract

This invention provides a cytochrome oxidase gene Grho7DLH, Grho7DLH protein, amplification primer set, and applications, belonging to the field of biotechnology. The Grho7DLH protein is derived from *Gentiana scabra*, and its amino acid sequence is shown in SEQ ID NO:2. The nucleotide sequence of the cytochrome oxidase gene Grho7DLH encoding the Grho7DLH protein is shown in SEQ ID NO:1. This invention obtains the Grho7DLH gene from *Gentiana scabra* and, through heterologous expression and in vitro enzymatic reactions, directly confirms that this protein can catalyze the oxidation of 7-deoxyserologous acid to loganic acid using NADPH as a coenzyme, filling the gap in the verification of the enzymatic function of 7DLH in Gentianaceae plants. This invention also identifies and discovers Grho7DLH, a key oxidase in *Gentiana scabra* involved in the biosynthesis of iridoid glycosides, revealing the catalytic mechanism of loganic acid formation in *Gentiana scabra* at the molecular level. This provides a clear gene target and theoretical basis for subsequent research on the quality formation rules of *Gentiana scabra* medicinal materials and for conducting molecular-assisted breeding.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and particularly relates to a cytochrome oxidase gene Grho7DLH, Grho7DLH protein, amplification primer set and application thereof. Background Art

[0002] Gentiana rhodantha ( Gentiana rhodantha Franch.) is a plant belonging to the genus Gentiana of the family Gentianaceae, the whole herb of which can be used as a medicine. It is mainly distributed in the southwest region, and has been included as a newly added traditional Chinese medicinal material in the 2015 edition, 2020 edition and 2025 edition of Chinese Pharmacopoeia. It is bitter and cold in nature, has the effects of clearing heat and dehumidifying, detoxifying, and relieving cough, and is used for treating damp-heat jaundice, dysuria, and cough due to lung heat. At present, compound compatibilities and traditional Chinese medicinal products related to Gentiana rhodantha have been widely developed, such as Feilike Mixture and Jiaolong Capsules. At present, the clinical application of Gentiana rhodantha mainly relies on the exploitation of its wild resources, and the quality of artificially cultivated Gentiana rhodantha is low and unstable. With the wide application of Gentiana rhodantha medicinal materials and preparations thereof, its wild resources are increasingly scarce, which seriously restricts the development of the Gentiana rhodantha industry.

[0003] Modern pharmacological studies have shown that iridoid glycosides have important pharmacological effects. Geniposide ( Gardenoside ) in Gardenia jasminoides of the Rubiaceae family can effectively protect liver function, and also has the effects of inhibiting inflammation, reducing blood glucose level, and protecting the central system; the iridoid glycoside contained in plants of the Cornaceae family can effectively prevent and treat various complications caused by diabetes, such as heart lesions, renal function and structural changes; while the iridoid glycosides of Gentianaceae plants have good pharmacological effects such as liver protection, anti-inflammation, antipyretic and antiviral effects. Gentiana rhodantha mainly grows on alpine slopes, thickets, roadside grasslands and under forests at an altitude of 400-1750m. Iridoid glycosides are important active components of Gentiana rhodantha, however, there is still a lack of in-depth research on its biosynthetic pathway and key enzymes.

[0004] Existing studies have shown that the biosynthetic pathway of iridoid glycosides is relatively complex, involving a variety of key enzyme genes. 7-deoxyloganic acid hydroxylase (7DLH) is a very important regulatory enzyme in the biosynthetic pathway of iridoid glycosides. 7DLH belongs to cytochrome P450 ( CytochromeThe P450 (CYP450) family is a class of key enzymes widely found in plants, involved in the biosynthesis of various bioactive metabolites, growth and development, and adaptation to stress. 7DLH in *Catharanthus roseus* (Apocynaceae) has been reported to catalyze the oxidation of 7-deoxyserologinate to loganic acid. However, the key enzyme catalyzing the oxidation of 7-deoxyserologinate to loganic acid in the biosynthetic pathway of iridoid glycosides in *Gentianaceae* plants remains undiscovered, requiring further research into the function and catalytic mechanism of 7DLH.

[0005] Therefore, in order to achieve sustainable and efficient production of iridoid glycosides, systematically identifying and characterizing the key 7DLH gene involved in their oxidative modification is a technical problem that urgently needs to be solved by those skilled in the art. Summary of the Invention

[0006] To address the aforementioned problems in the prior art, this invention provides a cytochrome oxidase gene Grho7DLH, Grho7DLH protein, amplification primer set, and its applications. This invention proposes cytochrome P450 and its encoding gene in *Gentiana scabra*, along with their applications, providing important evidence for a deeper understanding of the molecular mechanisms underlying the quality formation of *Gentiana scabra* medicinal materials. This not only helps elucidate the biosynthetic mechanism of iridoid glycosides but also lays the foundation for the green manufacturing of these high-value active ingredients through synthetic biology methods (such as microbial heterologous synthesis or plant metabolic engineering), which is of great significance for protecting wild resources and promoting the modernization of traditional Chinese medicine.

[0007] To achieve the above objectives, the present invention provides the following technical solution: This invention provides a protein derived from safflower gentian, the amino acid sequence of which is shown in SEQ ID NO:2.

[0008] The present invention provides a cytochrome oxidase gene encoding the protein, the nucleotide sequence of which is shown in SEQ ID NO:1.

[0009] The present invention names the protein Grho7DLH protein and the gene Grho7DLH gene, wherein the amino acid sequence of the Grho7DLH protein is as shown in SEQ ID NO:2, consisting of 516 amino acids; and the nucleotide sequence of the Grho7DLH gene is as shown in SEQ ID NO:1, containing 1548 nucleotides.

[0010] The present invention provides an expression cassette, recombinant expression vector or recombinant bacteria containing the gene.

[0011] The present invention provides an amplification primer for amplifying the gene, the amplification primer consisting of an upstream primer and a downstream primer, the nucleotide sequence of the upstream primer being shown in SEQ ID NO:3, and the nucleotide sequence of the downstream primer being shown in SEQ ID NO:4.

[0012] This invention provides the application of the protein or gene in catalyzing the oxidation of 7-deoxyserosolic acid to loganic acid.

[0013] Furthermore, the application specifically involves using reduced nicotinamide adenine dinucleotide phosphate (NADPH) as a coenzyme to catalyze the oxidation of the protein substrate 7-deoxyserotic acid to generate loganic acid.

[0014] This invention provides the application of the protein or gene in the biosynthesis of iridoid glycosides.

[0015] This invention provides a method for increasing the content of iridoid glycosides in gentian safflower by overexpressing the gene in gentian safflower or enhancing the activity of the protein.

[0016] This invention provides the application of the protein as a cytochrome oxidase.

[0017] Furthermore, the application is as follows: the cytochrome oxidase can catalyze the oxidation of 7-deoxyserologine to strychnine using NADPH as a coenzyme.

[0018] The beneficial effects of this invention compared to the prior art are as follows: This invention obtains the Grho7DLH gene from gentian and directly confirms through heterologous expression and in vitro enzymatic reaction that the protein can catalyze the oxidation of 7-deoxyserosolic acid to loganic acid using NADPH as a coenzyme, filling the gap in the verification of the enzymatic function of 7DLH in gentianaceae plants.

[0019] This invention has identified Grho7DLH, a key oxidase involved in the biosynthesis of iridoid glycosides in Gentiana scabra, and revealed the catalytic mechanism of loganic acid formation in Gentiana scabra at the molecular level. This provides clear gene targets and theoretical basis for subsequent research on the quality formation of Gentiana scabra medicinal materials and for carrying out molecular-assisted breeding.

[0020] The Grho7DLH protein and its encoding gene provided by this invention can serve as a key catalytic module in the synthetic biology framework. They can be used to construct heterologous synthetic pathways for loganic acid and even high-value iridoid glycosides such as swertiamarin and gentiopicrin in microbial hosts such as *E. coli* and yeast, and to perform metabolic engineering in plants to increase the yield of target active ingredients. The Grho7DLH provided by this invention is a P450 enzyme element with verified enzymatic function and well-defined catalytic activity. It can be directly used for the design and assembly of synthetic biology circuits, avoiding the uncertainty caused by inferring function solely based on sequence homology.

[0021] This invention, through the identification and application of the Grho7DLH gene, lays the foundation for the green and sustainable production of iridoid glycoside active ingredients through synthetic biology methods. It is expected to reduce the over-harvesting of wild gentian resources and is of great significance for protecting rare medicinal plant resources and promoting the modernization of traditional Chinese medicine. Attached Figure Description

[0022] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0023] Figure 1 This is the phylogenetic tree of the 7DLH gene in Example 1 of the present invention, with red pentagrams marking the position of Grho7DLH in the phylogenetic analysis; Figure 2 The images show agarose gel electrophoresis diagrams of the cloning and expression vector construction of the Grho7DLH gene in Example 2 of this invention. The left image is an agarose gel electrophoresis diagram of the Grho7DLH gene cloning, and the right image is a colony PCR agarose gel electrophoresis diagram of the colony transformed into the Trans1-T1 host after the pESC-His-Grho7DLH vector was constructed. Figure 3 This is an agarose gel electrophoresis image of the successful transformation of the pESC-His-Grho7DLH recombinant plasmid into WAT11 Saccharomyces cerevisiae colony PCR in Example 3 of the present invention. Figure 4 The structural formulas of 7-deoxyseromonoic acid and loganic acid in this invention are shown below; Figure 5 LC-MS analysis of the Grho7DLH-catalyzed 7-deoxystrychnine reaction product in Example 3 of this invention; Figure 6 This is a secondary mass spectrum of the product of the Grho7DLH-catalyzed 7-deoxystrychnosic acid reaction in Example 3 of the present invention. Detailed Implementation

[0024] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0025] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0026] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0027] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0028] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0029] Example 1: Screening of the 7DLH gene based on Gentiana safflower genome data Red gentian was collected from Leigong Mountain in southeastern Guizhou Province, and its genome was sequenced using the Illumina and PacBio platforms.

[0030] The CYP450 protein sequence of the plant was downloaded from the NCBI database and subjected to BLAST homology analysis with the Gentiana scabra genomics database. The Hidden Markov Model (HMM) file of the CYP450 protein was downloaded from Pfam, and HMMER software was used to search for protein sequences containing the PT.HMM (PF00067) domain. The results of the BLAST homology analysis and the HMMER domain search were combined, and sequences with similarity less than 30% and an e-value less than 10 were excluded. -5 The transcripts were sequences less than 300 amino acids in length. These transcripts were submitted to NCBI-CDD for verification of conserved domains of CYP450. The protein sequences obtained through the above screening steps were identified as members of the CYP450 gene family (GrhoCYPs) of *Gentiana safflower*.

[0031] Based on the genomic data of *Gentiana scabra*, a total of 380 GrhoCYP sequences were screened. The CYP family was divided according to amino acid sequence similarity (>40% similarity to the same family, >55% to the same subfamily). Currently reported 7DLH sequences in the plant kingdom all belong to the CYP72A subfamily. Based on phylogenetic analysis of the CYP72A subfamily (e.g.... Figure 1 As shown in the figure, Grho7DLH was further screened, which is speculated to have oxidase activity, and further functional characterization was carried out.

[0032] Example 2 Cloning and Construction of the Candidate Grho7DLH Gene and Expression Vector in Gentiana scabra The specific steps for cloning and constructing the expression vector of the candidate Grho7DLH gene from Gentiana scabra include: 1. Material design and reaction system The pESC-His-Grho7DLH expression vector was obtained using homologous recombination. Primer sequences Grho7DLH-F (SEQ ID NO:3) and Grho7DLH-R (SEQ ID NO:4) were designed, as shown in Table 1. Using cDNA from the root of *Gentiana scabra* as a template, the Grho7DLH gene fragment was cloned using KOD One™ PCR Master Mix (purchased from Toyobo (Shanghai) Biotechnology Co., Ltd., No. KMM-201). The total volume of the KOD high-fidelity enzyme PCR system was 50 μL: 25 μL KOD One™ PCR Master Mix, 1.5 μL primers (10 mM), 1 μL template, and 21 μL water. The PCR reaction program is shown in Table 2.

[0033] Table 1 Primer sequences used to clone the Grho7DLH gene

[0034] Table 2 KOD high-fidelity enzyme PCR reaction procedure

[0035] The target gene was constructed into the pESC-His vector using the ClonExpress II One Step Cloning Kit (purchased from Nanjing Novizan Biotechnology Co., Ltd., catalog number C112), with BamHI and SalⅠ restriction sites. According to the restriction endonuclease instructions (purchased from New England Biolabs, catalog number E8200S), the optimal molar ratio of cloning vector to insert fragment in this reaction system was 1:2. The optimal amount was calculated using the following formula: Optimal cloning vector usage = [0.02 × number of base pairs in the cloning vector] ng (0.03 pmol); Optimal amount of insert fragment used = [0.04 × number of base pairs of insert fragment] ng (0.06 pmol); The composition of this reaction system is shown in Table 3 after calculation: Table 3 Composition of the homologous recombination reaction system

[0036] After all components were added, the reaction solution was gently aspirated and mixed, then briefly centrifuged, and incubated at 37°C for 30 minutes to obtain the pESC-His-Grho7DLH recombinant product.

[0037] 2. Transformation of recombinant products (1) Thaw Trans1-T1 competent cells (purchased from Beijing TransGen Biotech Co., Ltd., product catalog number CD501-02) on ice. Aliquot 50 μL of thawed Trans1-T1 competent cells into pre-cooled 1.5 mL centrifuge tubes.

[0038] (2) Add 5 μL of the above pESC-His-Grho7DLH recombinant product to the centrifuge tube, mix gently, and incubate on ice for 30 minutes; then heat shock in a water bath at 42°C for 30 seconds, and then quickly transfer to an ice bath for 2 minutes without shaking the centrifuge tube during the transfer to obtain the transformed competent cells.

[0039] (3) Take 50 μL of the above-mentioned transformed competent cells, spread them evenly on ampicillin-resistant LB agar medium, and invert the plate in a 37°C incubator for 12-16 hours.

[0040] 3. Screening of positive clones (1) Select 4 single clones grown on the recombinant plate and place them in 200 μL of LB liquid medium (ampicillin resistant) and incubate at 37°C in a shaker for 2 hours (200 rpm).

[0041] (2) Colony PCR identification was performed using 2×Taq Mix DNA polymerase (purchased from Nanjing Novizan Biotechnology Co., Ltd., product catalog number P131-01). The amplification primer sequences designed using Primer 6.0 were: GAL1-F (SEQ ID NO.5): ATTTTCGGTTTGTATTACTTC; GAL1-R (SEQ ID NO.6): GTTCTTAATACTAACATAACT.

[0042] The standard PCR reaction system is shown in Table 4, and the standard PCR reaction procedure is shown in Table 5.

[0043] Table 4 Composition of a conventional PCR reaction system

[0044] Table 5. Conventional PCR Reaction Procedure

[0045] (3) Take 5 μL of PCR product for agarose gel electrophoresis. Refer to the DNA Marker (purchased from Beijing TransGen Biotech Co., Ltd., product catalog number BM111-01), select bacterial cultures with reasonable band positions and send them to Beijing Nuosai Genome Research Center Co., Ltd. for detection. Compare with RNA-seq sequences to obtain the final sequence information.

[0046] Grho7DLH was cloned using the primers in Table 1, and the results were detected by agarose gel electrophoresis. Figure 2 As shown in the figure. Sequencing yielded its sequence, and BLAST alignment revealed a 99% similarity between the nucleotide sequence and the original data. The actual sequencing result was taken as the definitive one. The actual sequencing result, as shown in SEQ ID NO.1, contains 1548 nucleotides, encoding the protein shown in SEQ ID NO.2, which consists of 516 amino acids. This gene was named the Grho7DLH gene, and the protein it encodes was named the Grho7DLH protein.

[0047] The nucleotide sequence of the Grho7DLH gene (SEQ ID NO:1) is as follows:

[0048] The amino acid sequence (SEQ ID NO:2) of the Grho7DLH protein is as follows: MGIDLEAFTITGLIAFSIYLVYRFLDWIWFTPKKLERFLRDQGLKGNPYRLYLGDQYESGKLIKQALSKPIGVEDDIKKRIVPHILKAVQTHGKESFMWVGRIPRIFVTDPELVREVLTKYYRFNKNHH GLDPITKFLLTGIGSLEGEPWSKRRKLITTAFQFEKLKLMLPAFYQSCRDLVTKWEAKVPKGASTEVEVWHDIETLTGDVIARTLFGSNYEEGKRIFELMRELTSLTIDVIRSVYIPGQRFLPTKRNTR MRAIDKEVRVLITEIIDKKMKVMKDGQTNASDFLGMLLECNRNEIQNQGDSRMSLEDIIGECKLFYFAGQDTTSTLLVWTMVLLSRYPEWQTRARKEVLEVFGDGQPDYDGISRLKVVTMILNEVLRLY TPVAELTKVAHEDTQLGKYKIPAGVQLMMPQILLHHDTTIWGDDAMEFNPERFIDGVMKATKSQGSFFPFSLGPRMCIGQNFAILEAKMAMALILRRFSFSLSPSYVHAPYTLITMQPQFGAHLILNKL.

[0049] Example 3 The functional validation of the candidate Grho7DLH gene was performed using the following steps: 1. Recombinant plasmid transformation The engineered Saccharomyces cerevisiae WAT11 was selected as the heterologous expression host for Grho7DLH. The specific steps for transforming the expression strain are as follows: (1) Carrier DNA pretreatment: Insert the carrier DNA into a 95℃ metal bath for 5 min, and then quickly insert it into ice after heating; (2) Take 100 μL of WAT11 competent cells thawed on ice, add 2-5 μg of pre-cooled target plasmid, 10 μL of pretreated carrier DNA, and 500 μL of PEG / LiAc in sequence, pipette and mix well, and incubate in a 30℃ water bath for 30 min (invert 6-8 times at 15 min to mix well). (3) Place the centrifuge tube in a water bath at 42°C for 15 min (tumble 6-8 times at 7.5 min to mix), then centrifuge at 5000 rpm for 40 s and remove the supernatant. (4) Add 400 μL ddH2O to resuspend, then centrifuge at 5000 rpm for 30 s and discard the supernatant. Then add 50 μL ddH2O to resuspend again. After that, spread it on SD-His solid medium (purchased from Beijing Pankino Technology Co., Ltd., product catalog number YGM003A-4, preparation method: weigh 8g of the purchased medium and 15g of agar powder, add water to 950mL, adjust pH to 6.0, autoclave at 121℃ for 20 minutes, add 50 mL of 40% filtered sterilized glucose solution, mix thoroughly, and incubate at 30℃ for 48-96 h; (5) Verification of positive clones: Select a single clone and incubate it in SD-His liquid medium at 200 rpm and 30℃ for about 24 h. Verify the positive clone by bacterial PCR.

[0050] 2. Induced expression (1) Select yeast positive single clones that have been verified to contain the pESC-His-Grho7DLH vector and culture them in 50 mL SD-His medium for 36-48 h; (2) Transfer the above yeast culture to 450 mL YPD medium (containing 1% glucose and 2% galactose), culture for 32 h, and then centrifuge at 4000 rpm for 6 min. (3) The yeast cells collected after centrifugation were washed sequentially with 40 mL TES buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA and 0.6 mM D-sorbitol) and 30 mL TES-M buffer (TES buffer solution with 30 mM β-mercaptoethanol added), and resuspended with 25 mL extraction buffer (TES buffer solution with 1% bovine serum albumin and 1 mM PMSF added); (4) Yeast cells were lysed using an ultra-high pressure cell disruptor. The supernatant was collected after centrifugation at 5000×g and 10000×g for 10 min at 4℃. Microsomes were then obtained by centrifugation at 120000×g for 90 min at 4℃. (5) Resuspend the particles containing microsomes in 1 mL of TEG-M buffer (containing 20% ​​(v / v) glycerol) and store at -80°C.

[0051] 3. Performance Testing (1) In vitro enzyme activity detection The obtained microsomes were used for functional validation according to the following reaction system: 200 μL microsomes, 0.5 mM NADPH and 2 μL substrate (1 mg / mL), incubated at 30 °C for 2 h. After terminating the reaction with an equal volume of methanol, the mixture was filtered through a 0.22 μm microporous membrane, and the sample was transferred to a liquid chromatography vial for analysis. The samples were analyzed using an Agilent 1290 Infinity II-6430 Q-TOF chromatogram. The specific liquid chromatography conditions were as follows: (1) Column: Ultimate® XB-C18 3 μm 2.1×100 mm; (2) Mobile phase: Phase A was 0.1% formic acid water, and Phase B was chromatographic acetonitrile; (3) Flow rate: 0.25 mL / min; (4) Column temperature: 40℃; (5) Injection volume: 1.0 μL; (6) Elution conditions are shown in Table 6; (7) Mass spectrometry conditions were as follows: Ion mode was positive ion, scan range was m / z 100-3000; mode was Automated MS / MS; ion fragment collision energy was 20V; source temperature was 350℃; nebulizer pressure was set to 30 psi. The results are as follows. Figure 3 As shown, by Figure 3 It can be seen that the recombinant plasmid pESC-His-Grho7DLH was successfully transferred into Saccharomyces cerevisiae.

[0052] Table 6. Elution gradient of mobile phase during LC-Q-TOF detection

[0053] Further enzyme activity analysis was conducted to identify the function of the Grho7DLH protein or the Grho7DLH gene. The enzyme activity reaction used NADPH as a cofactor and 7-deoxystrophic acid (C7DLH) as the active ingredient. 16 H 24 O9 (purchased from MedChemExpress, catalog number: HY-N11868) was used as a substrate to test whether it could be catalyzed to generate loganic acid (7-deoxyserologinic acid and the structural formula of loganic acid are shown below). Figure 4 The reaction products were analyzed using liquid chromatography-mass spectrometry (LC-MS), and the results are as follows. Figure 5 and Figure 6 As shown.

[0054] Compared to the microparticle catalytic system containing pESC-His empty support (negative control), in the Grho7DLH catalytic system, when 7-deoxyserologine was used as the substrate and NADPH as the cofactor donor, the detected product exhibited the same retention time and mass spectrometric fragmentation pattern as the loganic acid standard ([M+Na)). + The value of m / z = 399.1262 indicates that the product is loganic acid.

[0055] This revealed that Grho7DLH can catalyze the reaction of the substrate 7-deoxystrychic acid, and the product loganic acid was detected in the system.

[0056] In summary, based on mass spectrometry detection data and negative control results, Grho7DLH was determined to have the function of catalyzing the formation of loganic acid from 7-deoxystrychnine.

[0057] Compared with the detection results of the microparticle catalytic system containing pESC-His empty support, when 7-deoxyserologic acid was used as the substrate and NADPH was used as the cofactor donor, the product exhibited the same retention time and mass spectrometric fragmentation pattern as loganic acid ([M+Na)). + (m / z = 399.1262).

[0058] In summary, based on mass spectrometry data, it was determined that cytochrome oxidase transferase Grho7DLH has the function of catalyzing the conversion of 7-deoxyserologine to loganic acid.

[0059] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A protein derived from safflower gentian, characterized in that, The amino acid sequence of the protein is shown in SEQ ID NO:

2.

2. A cytochrome oxidase gene encoding the protein as described in claim 1, characterized in that, The nucleotide sequence of the gene is shown in SEQ ID NO:

1.

3. An expression cassette, recombinant expression vector, or recombinant bacteria containing the gene described in claim 2.

4. An amplification primer for amplifying the gene of claim 2, characterized in that, The amplification primers consist of an upstream primer and a downstream primer. The nucleotide sequence of the upstream primer is shown in SEQ ID NO:3, and the nucleotide sequence of the downstream primer is shown in SEQ ID NO:

4.

5. The use of the protein as described in claim 1 or the gene as described in claim 2 in catalyzing the oxidation of 7-deoxystrychnine to loganic acid.

6. The application according to claim 5, characterized in that, The specific application is as follows: using NADPH as a coenzyme, the protein catalyzes the oxidation of the substrate 7-deoxyseromonic acid to generate loganic acid.

7. The use of the protein as described in claim 1 or the gene as described in claim 2 in the biosynthesis of iridoid glycosides.

8. A method for increasing the content of iridoid glycosides in safflower gentian, characterized in that, Overexpression of the gene of claim 2 in gentian safflower, or enhancement of the activity of the protein of claim 1.

9. The use of the protein as a cytochrome oxidase as described in claim 1.

10. The application according to claim 9, characterized in that, The application is as follows: the cytochrome oxidase can use NADPH as a coenzyme to catalyze the oxidation of 7-deoxyserosolic acid to strychnine.